Skip to content

Study · Other design · 2021

5 results

Liraglutide pharmacokinetics and exposure-response in adolescents with obesity.

Carlsson Petri KC, Hale PM, Hesse D, Rathor N, Mastrandrea LD

Pediatric obesity7 May 2021Cited by 13 (Europe PMC)

PMID33963681 (opens in a new tab)PMCIDPMC8519033 (opens in a new tab)DOI10.1111/ijpo.12799 (opens in a new tab)PepBankPUB-33963681
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

BackgroundObesity in adolescence presents a major public health challenge, often leading to obesity in adulthood with associated chronic disease.ObjectivesThis study aimed to perform a population pharmacokinetic and exposure-response analysis of liraglutide by meta-analysis of data from trials conducted in children, adolescents and adults with obesity.MethodsThe population pharmacokinetic analysis investigated the effect of covariates body weight, age group (children, adolescents and adults) and sex on liraglutide exposure in adolescents compared with previous results in adults. The exposure-response relationship of liraglutide for the change from baseline in body mass index standard deviation score (BMI SDS) was evaluated in adolescents and compared to that in adults.ResultsBody weight was the main covariate affecting liraglutide exposure, with lower exposures at higher body weights, whereas age group was of no importance and sex was of little importance. An exposure-response relationship was demonstrated for liraglutide in both adolescents and adults as the decrease in BMI SDS from baseline increased in an exposure-dependent manner with increasing liraglutide exposure.ConclusionsThe population pharmacokinetic analysis supported similar liraglutide exposures in adolescents and adults; body weight was the most important covariate affecting exposure. An exposure-response relationship was established for liraglutide.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanOther designPharmacokinetics

    In children, adolescents and adults with obesity, body weight was the main covariate on liraglutide exposure, with lower exposures at higher body weights.

    In plain wordsIn young people and adults with obesity, people with higher body weight had lower liraglutide levels in the blood.

    Peptide
    Liraglutide
    Outcome
    DecreaseEffect of body weight on liraglutide exposure
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Body weight was the main covariate affecting liraglutide exposure, with lower exposures at higher body weights
    1 context sentence
    Summary · context
    This study aimed to perform a population pharmacokinetic and exposure-response analysis of liraglutide by meta-analysis of data from trials conducted in children, adolescents and adults with obesity.
  2. 02HumanOther designPharmacokinetics

    In children, adolescents and adults with obesity, age group was of no importance for liraglutide exposure.

    In plain wordsIn young people and adults with obesity, age group did not matter for liraglutide levels in the blood.

    Peptide
    Liraglutide
    Outcome
    No significant changeEffect of age group on liraglutide exposure
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas age group was of no importance and sex was of little importance.
    1 context sentence
    Summary · context
    This study aimed to perform a population pharmacokinetic and exposure-response analysis of liraglutide by meta-analysis of data from trials conducted in children, adolescents and adults with obesity.
  3. 03HumanOther designPharmacokinetics

    In children, adolescents and adults with obesity, sex was of little importance for liraglutide exposure.

    In plain wordsIn young people and adults with obesity, sex had little effect on liraglutide levels in the blood.

    Peptide
    Liraglutide
    Outcome
    No significant changeEffect of sex on liraglutide exposure
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas age group was of no importance and sex was of little importance.
    1 context sentence
    Summary · context
    This study aimed to perform a population pharmacokinetic and exposure-response analysis of liraglutide by meta-analysis of data from trials conducted in children, adolescents and adults with obesity.
  4. 04HumanOther designPharmacokinetics

    In adolescents with obesity, the population pharmacokinetic analysis supported similar liraglutide exposures as in adults.

    In plain wordsIn adolescents with obesity, liraglutide levels in the blood were similar to those in adults.

    Peptide
    Liraglutide
    Outcome
    No significant changeLiraglutide exposure in adolescents compared with adults
    Study

    n: not reported in source

    Comparator
    Adults
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The population pharmacokinetic analysis supported similar liraglutide exposures in adolescents and adults; body weight was the most important covariate affecting exposure.
    1 context sentence
    Summary · context
    This study aimed to perform a population pharmacokinetic and exposure-response analysis of liraglutide by meta-analysis of data from trials conducted in children, adolescents and adults with obesity.
  5. 05HumanOther designEfficacy outcome

    In adolescents and adults with obesity, the decrease in BMI SDS from baseline increased in an exposure-dependent manner with increasing liraglutide exposure.

    In plain wordsIn adolescents and adults with obesity, higher liraglutide levels in the blood were linked to a larger drop in BMI score.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI SDS change by liraglutide exposure
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    An exposure-response relationship was demonstrated for liraglutide in both adolescents and adults as the decrease in BMI SDS from baseline increased in an exposure-dependent manner with increasing liraglutide exposure.
    1 context sentence
    Summary · context
    This study aimed to perform a population pharmacokinetic and exposure-response analysis of liraglutide by meta-analysis of data from trials conducted in children, adolescents and adults with obesity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.